Log In
BCIQ
Print this Print this
 

KVD001

  Manage Alerts
Collapse Summary General Information
Company KalVista Pharmaceuticals Inc.
DescriptionIntravitreal plasma kallikrein inhibitor
Molecular Target Kallikrein
Mechanism of ActionKallikrein inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase I
Standard IndicationDiabetic macular edema (DME)
Indication DetailsTreat diabetic macular edema (DME)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

$2.2M

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

11/22/2016

Undisclosed

Undisclosed

Undisclosed

01/16/2012

$2.2M

0

0

Get a free BioCentury trial today